How to Get Rezdiffra (Resmetirom) in Tennessee

What Is Rezdiffra and Why Does It Matter for Tennessee Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral medication specifically targeting MASH, a progressive liver disease affecting an estimated 6 to 8 million Americans with moderate-to-advanced fibrosis [1]. The FDA granted approval on March 14, 2024, based on the MAESTRO-NASH trial, a Phase 3 study (N=966) that demonstrated NASH resolution without worsening fibrosis in 25.9% of patients receiving the 80 mg dose and 29.9% receiving the 100 mg dose, compared to 9.7% with placebo at 52 weeks [1].

Tennessee carries a significant MASH burden. The state ranks among the top 15 nationally for obesity prevalence, with 36.4% of adults classified as obese according to CDC data, and obesity is a primary driver of MASH progression [2]. Before resmetirom, Tennessee patients with advancing fibrosis had no FDA-approved pharmacotherapy. Their options were lifestyle modification or liver transplant evaluation once cirrhosis developed. Rezdiffra fills that gap for patients at fibrosis stages F2 and F3, the window where halting progression can prevent cirrhosis altogether.

The FDA prescribing label specifies weight-based dosing: 80 mg once daily for patients weighing less than 100 kg, and 100 mg once daily for those at or above 100 kg [3].

Step-by-Step: Getting a Rezdiffra Prescription in Tennessee

The process from initial evaluation to filled prescription typically involves four stages. Each one has specific requirements that Tennessee patients should prepare for.

Stage 1: Establish a qualifying diagnosis. A prescriber must confirm MASH with stage F2 or F3 fibrosis. Liver biopsy remains the gold standard for fibrosis staging, though the American Association for the Study of Liver Diseases (AASLD) acknowledges noninvasive methods including FibroScan (vibration-controlled transient elastography) and the FIB-4 index as validated screening tools [4]. Many Tennessee gastroenterology and hepatology practices, including those affiliated with Vanderbilt University Medical Center and UT Medical Center in Knoxville, offer FibroScan in-office.

Stage 2: Obtain a prescription. Any Tennessee-licensed MD, DO, NP, or PA with prescriptive authority can write a resmetirom prescription. Tennessee Board of Medical Examiners rules do not restrict this drug to hepatology subspecialists, though most prescribers to date are gastroenterologists or hepatologists with experience managing fibrotic liver disease.

Stage 3: Complete prior authorization. Most commercial plans and pharmacy benefit managers require prior authorization (PA). This step typically takes 5 to 15 business days. Expect your prescriber's office to submit clinical documentation supporting the diagnosis.

Stage 4: Fill at a participating pharmacy. Rezdiffra is classified as a specialty medication by most payers. Patients often fill through specialty pharmacies, though retail pharmacies that stock it can also dispense.

Telehealth Access to Rezdiffra in Tennessee

Tennessee law permits telehealth prescribing for resmetirom. This is a real option, not a workaround.

The Tennessee General Assembly updated its telehealth statute (Tenn. Code Ann. § 63-1-155) to allow practitioners to establish a provider-patient relationship via synchronous audio-video consultation. A prescriber licensed in Tennessee can evaluate a patient, review existing lab work and imaging, and write a Rezdiffra prescription without an in-person visit, provided the standard of care is met [5].

Telehealth is particularly relevant for patients in rural West Tennessee and Appalachian counties where gastroenterology and hepatology specialists are scarce. According to the Health Resources and Services Administration (HRSA), 58 of Tennessee's 95 counties are designated Health Professional Shortage Areas for primary care, and subspecialty access is even more limited [6].

A telehealth prescriber will still require documentation of fibrosis staging before writing a prescription. Patients should have their FibroScan results, FIB-4 score, or biopsy pathology report available for the virtual visit. Some telehealth platforms coordinate lab orders directly with Tennessee-based draw stations.

One practical note: if using a telehealth provider based outside Tennessee, confirm the prescriber holds an active Tennessee medical license. Out-of-state licensure alone does not authorize prescribing within Tennessee.

Required Labs Before Starting Rezdiffra

Lab work serves two purposes. It confirms eligibility and establishes a safety baseline. The FDA label and clinical trial protocols specify several tests [3].

Fibrosis staging (mandatory for diagnosis):

• FibroScan with controlled attenuation parameter (CAP) score
• FIB-4 index (calculated from age, AST, ALT, platelet count)
• Liver biopsy (if noninvasive results are indeterminate or if the insurer requires biopsy for PA)

Baseline liver function panel:

• ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin

Thyroid function tests: Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. While it was engineered to avoid systemic thyroid effects, the FDA label recommends baseline TSH and free T4 measurement. In MAESTRO-NASH, TSH remained within normal range for 95% of treated patients, but monitoring is required [1].

Lipid panel: Resmetirom significantly reduces LDL cholesterol, triglycerides, and lipoprotein(a). In MAESTRO-NASH, LDL cholesterol dropped by 13.6% at the 80 mg dose and 16.3% at 100 mg versus placebo at week 24 [1]. Baseline lipids help track this secondary benefit.

Additional labs based on clinical judgment: hepatitis B and C serologies (to rule out viral hepatitis as the etiology), hemoglobin A1c (given MASH's overlap with type 2 diabetes), and a complete metabolic panel.

Most Tennessee commercial labs, including Quest Diagnostics and Labcorp locations across the state, can process these panels. Results are typically available within 48 to 72 hours.

Tennessee Pharmacy Options: Specialty, Retail, and 503A Compounding

Filling a Rezdiffra prescription in Tennessee involves choosing the right pharmacy channel. Three pathways exist.

Specialty pharmacies are the most common dispensing channel. Madrigal Pharmaceuticals established a network of specialty pharmacy partners for Rezdiffra distribution. These pharmacies handle prior authorization coordination, copay card enrollment, and direct-to-patient shipping. Tennessee patients can receive the medication at their home address through these services.

Retail pharmacies can dispense Rezdiffra if they stock it, though availability varies. Large chain pharmacies in Nashville, Memphis, Knoxville, and Chattanooga are more likely to carry specialty medications than rural independents. Patients should call ahead.

503A compounding pharmacies in Tennessee are licensed by the Tennessee Board of Pharmacy and may compound resmetirom formulations under specific conditions. Tennessee's 503A regulations align with federal Section 503A of the FD&C Act: a licensed pharmacist may compound a drug based on a valid patient-specific prescription, using bulk drug substances that meet USP-NF standards [7]. This pathway can sometimes offer cost advantages, though patients should verify with their prescriber that a compounded formulation meets clinical standards. 503A compounded products cannot be shipped across state lines unless the pharmacy also holds a nonresident pharmacy license in the receiving state.

Insurance Coverage and Prior Authorization in Tennessee

Coverage varies sharply by payer type. Understanding the distinctions saves time.

Commercial insurance: Most major plans covering Tennessee residents, including BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, and Aetna, classify Rezdiffra as a specialty tier drug requiring prior authorization. Typical PA criteria include:

• Confirmed MASH diagnosis via biopsy or validated noninvasive biomarkers
• Fibrosis stage F2 or F3 (not F0, F1, or F4/cirrhosis)
• Documentation that the patient has attempted lifestyle modifications
• Prescriber is a hepatologist, gastroenterologist, or endocrinologist (some plans accept any licensed prescriber)
• Baseline lab work on file

The PA submission should include the pathology report or FibroScan result, relevant lab values, a letter of medical necessity from the prescriber, and the patient's BMI and comorbidity profile. Turnaround ranges from 5 to 15 business days. If denied, Tennessee patients have the right to appeal under the state's Utilization Review Act.

Tennessee Medicaid (TennCare): As of this writing, TennCare does not cover Rezdiffra for MASH. Coverage exists only for type 2 diabetes indications. Patients enrolled in TennCare who need resmetirom for MASH should explore Madrigal's patient assistance programs or 503A compounding as alternative access routes.

Medicare Part D: Coverage depends on the specific Part D plan. Resmetirom is on some formularies as a specialty tier drug with prior authorization. Medicare patients should check their plan's formulary or contact 1-800-MEDICARE.

According to the Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity, treatment decisions for MASH should integrate fibrosis severity, metabolic comorbidities, and patient access to medications when selecting therapy [8].

Cost, Copay Assistance, and Patient Support

Rezdiffra's wholesale acquisition cost is approximately $47,400 per year. Out-of-pocket costs depend heavily on insurance structure.

Madrigal Pharmaceuticals offers a copay assistance program for commercially insured patients that can reduce out-of-pocket costs to as low as $0 per month for eligible patients. The program has income and insurance-type requirements. Medicare, Medicaid, and other government-insured patients are not eligible for copay cards under federal anti-kickback statute restrictions.

For uninsured Tennessee patients, Madrigal's patient assistance program may provide the drug at no cost if household income falls below specified thresholds. Application typically requires proof of income, a valid prescription, and documentation of insurance denial or lack of coverage.

Tennessee patients may also investigate clinical trial enrollment. The ClinicalTrials.gov registry lists ongoing studies involving resmetirom, some of which provide the medication at no cost. The MAESTRO-NASH long-term extension study and other Madrigal-sponsored trials have active sites in the southeastern United States [9].

Who Can Prescribe Rezdiffra in Tennessee: MD vs. NP vs. PA

Tennessee does not restrict resmetirom prescribing to physicians alone. The scope of prescriptive authority breaks down as follows.

MDs and DOs hold full, unrestricted prescriptive authority in Tennessee for any FDA-approved medication. No collaborative agreement is needed.

Nurse Practitioners (NPs) gained full practice authority in Tennessee under the APRN Compact and state law amendments effective in recent years. NPs with a current Tennessee APRN license and DEA registration (if applicable) can prescribe resmetirom independently.

Physician Assistants (PAs) in Tennessee prescribe under a collaborative agreement with a supervising physician. The agreement must include prescriptive authority for the drug class that includes resmetirom. PAs can prescribe it as long as their supervising physician's scope covers hepatology, gastroenterology, or internal medicine.

In practice, most Rezdiffra prescriptions originate from gastroenterologists or hepatologists because the drug's indication requires subspecialty-level diagnostic workup. But a primary care provider who has confirmed the diagnosis through appropriate testing is legally permitted to write the prescription.

Timeline: From First Appointment to First Dose

The total elapsed time from initial evaluation to taking the first tablet of Rezdiffra depends on several variables. Here is a realistic breakdown for Tennessee patients.

• Initial evaluation and lab orders: 1 visit (in-person or telehealth), plus 2 to 5 days for lab results
• FibroScan or imaging: scheduling may add 1 to 3 weeks depending on facility availability; some offices perform FibroScan same-day
• Liver biopsy (if needed): scheduling typically adds 2 to 4 weeks, with 5 to 7 days for pathology results
• Prescription written: same day as diagnosis confirmation or at a follow-up visit
• Prior authorization: 5 to 15 business days for initial determination
• Pharmacy fulfillment and shipping: 3 to 7 business days after PA approval

Best-case scenario (FibroScan available, commercial insurance with fast PA): approximately 2 to 3 weeks from first visit to first dose.

Longer scenario (biopsy required, PA initially denied and appealed): 8 to 12 weeks.

Patients can accelerate the process by arriving at their first appointment with recent lab work, any prior imaging of the liver, and insurance information ready for the PA submission.

Transferring a Rezdiffra Prescription to Tennessee

Patients relocating to Tennessee or visiting from another state can transfer an existing resmetirom prescription. Tennessee Board of Pharmacy rules allow prescription transfers between licensed pharmacies. The receiving Tennessee pharmacy contacts the originating pharmacy, verifies the prescription details, and processes the transfer.

For specialty pharmacy prescriptions, the transfer may require re-enrollment in the specialty pharmacy's program and a new prior authorization under the patient's Tennessee-based insurance plan. If the patient's insurance plan did not change, the existing PA may carry over. Confirm with both the specialty pharmacy and the insurer before assuming coverage will transfer automatically.

Patients using telehealth providers should verify that their prescriber is licensed in Tennessee or establish care with a Tennessee-licensed prescriber before the current prescription's refills expire.